Breaking the rules: The unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies

Rheumatology

Volumn 42, Issue 3, 2003, Pages 404-412

  Boyle, L H ^a   Gaston, J S Hill ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HLA B27; Major histocompatibility complex; Spondyloarthropathy; T lymphocytes

Indexed keywords

BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DIMER; HLA B27 ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

ANIMAL MODEL; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; HUMAN; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; T LYMPHOCYTE; TRANSGENIC ANIMAL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HLA-B27 ANTIGEN; HUMANS; SPONDYLARTHROPATHIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037352593     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg097     Document Type: Review

References (89)

1. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704-6.
2. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
3. Storey GO, Scott DL. Arthritis associated with venereal disease in nineteenth century London. Clin Rheumatol 1998;17:500-4.
4. Kvien TK, Glennas A, Melby K et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 1994;21:115-22.
5. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993;342:646-50.
6. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 1997;159:5715-23.
7. Kuon W, Holzhutter HG, Appel H et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol 2001;167:4738-46.
8. Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest 2000;106:47-53.
9. Carreno BM, Solheim JC, Harris M, Stroynowski I, Connolly JM, Hansen TH. TAP associates with a unique class I conformation, whereas calnexin associates with multiple class I forms in mouse and man. J Immunol 1995;155:4726-33.
10. Anderson KS, Alexander J, Wei M, Cresswell P. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 1993;151:3407-19.
11. Wang J, Yu DT, Fukazawa T et al. A monoclonal antibody that recognizes HLA-B27 in the context of peptides. J Immunol 1994;152:1197-205.
12. Purcell AW, Kelly AJ, Peh CA, Dudek NL, McCluskey J. Endogenous and exogenous factors contributing to the surface expression of HLA B27 on mutant APC. Hum Immunol 2000;61:120-30.
13. Peh CA, Burrows SR, Barnden M et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998;8:531-42.
14. Beier DC, Cox JH, Vining DR, Cresswell P, Engelhard VH. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 1994;152:3862-72.
15. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999;162:5049-52.
16. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. Proc Natl Acad Sci USA 1993;90:6879-83.
17. Archer JR, Whelan MA, Badakere SS, McLean IL, Archer IV, Winrow VR. Effect of a free sulphydryl group on expression of HLA-B27 specificity. Scand J Rheumatol Suppl 1990;87:44-50.
18. MacLean L, Macey M, Lowdell M et al. Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry. Ann Rheum Dis 1992;51:456-60.
19. Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991;353:321-5.
20. Benjamin RJ, Madrigal JA, Parham P. Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 1991;351:74-7.
21. Frumento G, Harris PE, Gawinowicz MA, Suciu-Foca N, Pernis B. Sequence of a prominent 16-residue self-peptide bound to HLA-B27 in a lymphoblastoid cell line. Cell Immunol 1993;152:623-6.
22. Urban RG, Chicz RM, Lane WS et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994;91:1534-8.
23. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999;162:5045-8.
24. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
25. Carreno BM, Hansen TH. Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. Eur J Immunol 1994;24:1285-92.
26. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools for genetic analysis. Cell 1978;14:9-20.
27. Dangoria NS, DeLay ML, Kingsbury DJ et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002;277:23459-68.
28. Reinelt S, Dedier S, Asuni G, Folkers G, Rognan D. Mutation of Cys-67 alters the thermodynamic stability of the human leukocyte antigen HLA-B*2705. J Biol Chem 2001;276:18472-7.
29. Alvarez I, Marti M, Vazquez J, Camafeita E, Ogueta S, Lopez de Castro JA. The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation. J Biol Chem 2001;276:48740-7.
30. 2m. J Clin Invest 1996;98:2746-55.
31. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993;150:4168-78.
32. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
33. Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995;182:1153-8.
34. Simmons WA, Leong LY, Satumtira N et al. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1996;156:1661-7.
35. Taurog JD, Hammer RE, Ricardson JA et al. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1999;163:5741.
36. Khare SD, Lee S, Bull MJ, Hanson J, Luthra HS, David CS. Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides. Clin Immunol 2001;98:364-9.
37. Zhou M, Sayad A, Simmons WA et al. The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 1998;188:877-86.
38. Breban M, Fernandez-Sueiro JL, Richardson JA et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996;156:794-803.
39. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. J Immunol 1998;160:101-6.
40. Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics 1999;50:220-7.
41. Edwards JC, Bowness P, Archer JR. Jekyll and Hyde: the transformation of HLA-B27. Immunol Today 2000;21:256-60.
42. Allen RL, Gillespie GM, Hall F et al. Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. J Rheumatol 1997;24:1750-7.
43. Beacock-Sharp H, Young JL, Gaston JS. Analysis of T cell subsets present in the peripheral blood and synovial fluid of reactive arthritis patients. Ann Rheum Dis 1998;57:100-6.
44. Boyle LH, Goodall JC, Opat SS, Gaston JS. The recognition of HLA-B27 by human CD4(+) T lymphocytes. J Immunol 2001;167:2619-24.
45. De Bueger M, Bakker A, Goulmy E. Existence of mature human CD4 + T cells with genuine class I restriction. Eur J Immunol 1992;22:875-8.
46. Wang P, Vanky F, Klein E. MHC class-I-restricted auto-tumor-specific CD4 + CD8 - T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC). Int J Cancer 1992;51:962-7.
47. LeMay LG, Kan-Mitchell J, Goedegebuure P, Harel W, Mitchell MS. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol Immunother 1993;37:187-94.
48. Darrow TL, Abdel-Wahab Z, Quinn-Allen MA, Seigler HF. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. Cell Immunol 1996;172:52-9.
49. Nishimura MI, Avichezer D, Custer MC et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999;59:6230-8.
50. Kobayashi H, Kimura S, Aoki N, Sato K, Celis E, Katagiri M. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells. Immunogenetics 2001;53:626-33.
51. Trobonjaca Z, Leithauser F, Moller P et al. MHC-II-independent CD4(+) T cells induce colitis in immunodeficient RAG(-/-) hosts. J Immunol 2001;166:3804-12.
52. Chen HL, Gabrilovich D, Virmani A et al. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 1996;67:756-63.
53. Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994;91:4751-6.
54. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998;101:2720-9.
55. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today 1997;18:292-9.
56. Ahn K, Gruhler A, Galocha B et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-21.
57. Hengel H, Koopmann JO, Flohr T et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-32.
58. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA 1997;94:6904-9.
59. Hill A, Jugovic P, York I et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-5.
60. Zeidler R, Eissner G, Meissner P et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997;90:2390-7.
61. Petersson M, Charo J, Salazar-Onfray F et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998;161:2099-105.
62. Caspar-Bauguil S, Puissant B, Nazzal D et al. Chlamydia pneumoniae induces interleukin-10 production that down-regulates major histocompatibility complex class I expression. J Infect Dis 2000;182:1394-401.
63. Maksymowych WP, Tao S, Vaile J, Suarez-Almazor M, Ramos-Remus C, Russell AS. LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis. J Rheumatol 2000;27:183-9.
64. Maksymowych WP, Jhangri GS, Gorodezky C et al. The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis. Ann Rheum Dis 1997;56:488-92.
65. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA. Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheum 1995;38:684-9.
66. Maksymowych WP, Tao S, Li Y, Wing M, Russell AS. Allelic variation at the TAP 1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995;45:328-32.
67. Westman P, Partanen J, Leirisalo-Repo M, Koskimies S. TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Hum Immunol 1995;44:236-42.
68. Burney RO, Pile KD, Gibson K et al. Analysis of the MHC class II encoded components of the HLA class I antigen processing pathway in ankylosing spondylitis. Ann Rheum Dis 1994;53:58-60.
69. Nishioka K, Nakajima T, Hasunuma T, Sato K. Rheumatic manifestation of human leukemia virus infection. Rheum Dis Clin North Am 1993;19:489-503.
70. Scotet E, Peyrat MA, Saulquin X et al. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur J Immunol 1999;29:973-85.
71. Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985;313:1117-23.
72. Luxembourg A, Cailla H, Roux H, Roudier J. Do viruses play an etiologic role in ankylosing spondylitis or psoriatic arthritis? Clin Immunol Immunopathol 1987;45:292-5.
73. Welsh J, Avakian H, Cowling P et al. Ankylosing spondylitis, HLA-B27 and Klebsiella. I. Cross-reactivity studies with rabbit antisera. Br J Exp Pathol 1980;61:85-91.
74. Schwimmbeck PL, Yu DT, Oldstone MB. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987;166:173-81.
75. Chen JH, Kono DH, Yong Z, Park MS, Oldstone MM, Yu DT. A Yersinia pseudotuberculosis protein which cross-reacts with HLA-B27. J Immunol 1987;139:3003-11.
76. Zhong G, Liu L, Fan T, Fan P, Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000;191:1525-34.
77. Laval SH, Timms A, Edwards S et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001;68:918-26.
78. Ramos M, Paradela A, Vazquez M, Marina A, Vazquez J, Lopez De Castro JA. Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J Biol Chem 2002;277:28749-56.
79. Sesma L, Montserrat V, Lamas JR, Marina A, Vazquez J, Lopez de Castro JA. The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions. J Biol Chem 2002;277:16744-9.
80. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998;352:1137-40.
81. Khare SD, Luthra HS, David CS. HLA-B27 and other predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 1998;10:282-91.
82. Ljunggren HG, Glas R, Sandberg JK, Karre K. Reactivity and specificity of CD8 + T cells in mice with defects in the MHC class I antigen-presenting pathway. Immunol Rev 1996;151:123-48.
83. van Eggermond MC, Rijkers GT, Kuis W, Zegers BJ, van den Elsen PJ. T cell development in a major histocompatibility complex class II-deficient patient. Eur J Immunol 1993;23:2585-91.
84. Lopez D, Barber DF, Villadangos JA, Lopez de Castro JA. Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2. J Immunol 1993;150:2675-86.
85. Aparicio P, Jaraquemada D, Lopez de Castro JA. Alloreactive cytolytic T cell clones with dual recognition of HLA-B27 and HLA-DR2 antigens. Selective involvement of CD8 in their class I-directed cytotoxicity. J Exp Med 1987;165:428-43.
86. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93:2264-71.
87. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
88. Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med 1999;189:877-82.
89. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001;167:5543-7.